Cypherusa
WebTerms of Use. Contact. Technical Support WebFor additional information on the CYPHER Stent, visit www.CYPHERUSA.com or call 1-800-781-0282. * Cordis has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including. delivery via vascular stenting. Sirolimus, the active drug released
Cypherusa
Did you know?
WebSynonyms for cypher in Free Thesaurus. Antonyms for cypher. 36 synonyms for cypher: 0, nought, zero, cipher, goose egg, nada, naught, nil, nix, nothing, null, zero ... WebMar 13, 2006 · More information about the CYPHER(R) Stent can be found at www.cypherusa.com. About Cordis Corporation. Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians …
http://www.ptca.org/pr_jnj/20050420.html http://www.ptca.org/pr_jnj/20060202.html
WebMar 13, 2006 · ATLANTA, March 12 /PRNewswire/ -- The CYPHER(R) Sirolimus-eluting Coronary Stent reduced the risk of target vessel failure (TVF) by almost half in patients who suffered a heart attack (acute myocardial infarction or AMI) compared to those who were treated with the current standard of care (balloon angioplasty and a bare metal stent), … WebApr 26, 2006 · Miami, FL (April 26, 2006) – Two million patients have received the CYPHER® Sirolimus-eluting Coronary Stent since its market introduction in Europe in April 2002, a first-time milestone for any company in the drug-eluting stent industry. The CYPHER® Stent is the world leading drug-eluting stent for the treatment of coronary …
WebMIAMI, Sep 24, 2004 /PRNewswire via COMTEX/ -- The body of clinical evidence for the CYPHER(R) Sirolimus-eluting Coronary Stent continues to grow as new data from around the world are presented at the Cardiovascular Research Foundation's (CRF) Sixteenth Annual Scientific Symposium, Transcatheter
WebMIAMI, Mar 31, 2004 /PRNewswire-FirstCall via COMTEX/ -- Cordis Corporation, a Johnson & Johnson company, reported today it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its … shulman michaelWebJan 23, 2006 · The CYPHER® SELECT™ Sirolimus-eluting Coronary Stent, which is the first next generation drug-eluting stent, was launched in Europe, Asia Pacific, Latin … the outer beltWebTHE CYPHER COMPANY the outer banks north carolina rentalsWebOct 14, 2005 · MIAMI, Oct. 14-- Cordis Corporation today announced the schedule of key clinical presentations focusing on the safety and efficacy of the CYPHER® Sirolimus-eluting Coronary Stent in patients with complex coronary lesions.The new data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT 2005) Scientific Symposium in … the outer body is divided into what regionsWebApr 20, 2005 · In clinical trials, the CYPHER® Stent has been shown to reduce reblockage in the arteries by more than 90 percent over a conventional bare metal stent. More … shulman method for vmat planningthe outer boyshttp://www.ptca.org/pr_jnj/20060123.html shulman pediatrics